Delivery of therapeutic agents such as anti-VEGF antibodies, genes, or siRNA for degenerative diseases such as age-related macular degeneration could be applications with a good opportunity to improve therapeutic outcomes. The gene discussed is VEGFA; the disease is neurodegenerative disease.